Wealth Alliance Advisory Group’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Wealth Alliance Advisory Group’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,683	Closed	-$33.5K	–	185
2023 Q1	$33.5K	Sell	3,683 -1,459	-28%	-$20.7K	0.01%	162
2022 Q4	$60.3K	Sell	5,142 -1,291	-20%	-$22.8K	0.02%	162
2022 Q3	$136K	Buy	6,433 +6,033	+1,508%	+$163K	0.06%	143
2022 Q2	$10K	Hold	400	–	–	﹤0.01%	146
2022 Q1	$20K	Hold	400	–	–	0.01%	155
2021 Q4	$28K	Buy	+400	New	+$33.7K	0.01%	165

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wealth Alliance Advisory Group's VBIV Position: Q2 2023 in Review

Wealth Alliance Advisory Group sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 3,683 shares — an estimated $33.5K sold.

Wealth Alliance Advisory Group first reported a position in VBIV in Q4 2021 and held it in 6 quarters. The position peaked at $136K in Q3 2022. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

Wealth Alliance Advisory Group reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
Wealth Alliance Advisory Group sold 3,683 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $33.5K.
Wealth Alliance Advisory Group first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2021 and held it in 6 quarters.
Wealth Alliance Advisory Group's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $136K in Q3 2022.
46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Wealth Alliance Advisory Group's 13F filing for Q2 2023, filed 13 Jul 2023.